Is There a Place for Medicinal Cannabis in Treating Patients with Sleep Disorders? What We Know so Far

被引:10
|
作者
Maddison, Kathleen J. [1 ,2 ]
Kosky, Christopher [1 ]
Walsh, Jennifer H. [1 ,2 ]
机构
[1] Sir Charles Gairdner Hosp, West Australian Sleep Disorders Res Inst, Dept Pulm Physiol & Sleep Med, Perth, WA, Australia
[2] Univ Western Australia, Ctr Sleep Sci, Perth, WA, Australia
来源
NATURE AND SCIENCE OF SLEEP | 2022年 / 14卷
关键词
cannabinoid; insomnia; obstructive sleep apnea; restless legs syndrome; REM behavior disorder; nightmare disorder; BEHAVIOR DISORDER; REM-SLEEP; ADMINISTERED DELTA-9-TETRAHYDROCANNABINOL; NIGHTMARE DISORDER; AMERICAN ACADEMY; PRACTICE GUIDE; DOUBLE-BLIND; CHRONIC PAIN; MARIJUANA; EFFICACY;
D O I
10.2147/NSS.S340949
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The legalization of cannabis for medicinal, and in some countries, recreational, purposes in addition to growth in the cannabis industry has meant that cannabis use and interest in the area has increased rapidly over the past 20 years. Treatment of poor sleep and sleep disorders are two of the most common reasons for the current use of medicinal cannabis. However, evidence for the role of medical cannabis in the treatment of sleep disorders has not been clearly established, thus making it challenging for clinicians to make evidence-based decisions regarding efficacy and safety. This narrative review summarizes the highest quality clinical evidence currently available in relation to the use of medicinal cannabis for the treatment of sleep disorders including insomnia, obstructive sleep apnea, restless legs syndrome, rapid eye movement sleep behavior disorder, nightmare disorder and narcolepsy. A summary of the effect of cannabis on sleep quality and architecture is also presented. Currently, there is insufficient evidence to support the routine use of medicinal cannabis as an effective and safe treatment option for any sleep disorder. Nevertheless, emerging evidence is promising and warrants further investigation using standardized cannabinoid products and validated quantitative measurement techniques.
引用
收藏
页码:957 / 968
页数:12
相关论文
共 50 条
  • [41] Psychiatric Disorders and Comorbid Cannabis Use: When Should We Be Concerned and What Can We Do About It?
    Satre, Derek D.
    Borsari, Brian
    Tompkins, D. Andrew
    Ramo, Danielle
    JOURNAL OF CLINICAL PSYCHIATRY, 2018, 79 (06)
  • [42] Sepsis in veterinary patients: what do we know and where can we go?
    Otto, Cynthia M.
    JOURNAL OF VETERINARY EMERGENCY AND CRITICAL CARE, 2007, 17 (04) : 329 - 332
  • [43] Sleep-related breathing disorders. What the oral and maxillofacial surgeon should know
    Boeing, S.
    Randerath, W. J.
    MKG-CHIRURG, 2014, 7 (02): : 87 - 94
  • [44] What cancer patients actually know regarding medical cannabis? A cross-sectional survey with a critical analysis of the current attitudes
    Cortellini, Alessio
    Porzio, Giampiero
    Cofini, Vincenza
    Necozione, Stefano
    Giusti, Raffaele
    Marchetti, Paolo
    Spiriti, Maria A. Aloe
    Costanzi, Andrea
    Peris, Flaminia
    Ravoni, Giulio
    Spinelli, Giuseppe
    Ficorella, Corrado
    Verna, Lucilla
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (06) : 1439 - 1444
  • [45] Role of biologics targeting type 2 airway inflammation in asthma: what have we learned so far?
    Parulekar, Amit D.
    Diamant, Zuzana
    Hanania, Nicola A.
    CURRENT OPINION IN PULMONARY MEDICINE, 2017, 23 (01) : 3 - 11
  • [46] Mesenchymal stromal cells: what have we learned so far about their therapeutic potential and mechanisms of action?
    Amadeo, Francesco
    Cepeda, Katherine Trivino
    Littlewood, James
    Wilm, Bettina
    Taylor, Arthur
    Murray, Patricia
    EMERGING TOPICS IN LIFE SCIENCES, 2021, 5 (04) : 549 - 562
  • [47] What do we know about opportunities and challenges for localities from Cannabis legalization?(sic)(sic)(sic)Palabras clave
    Kavousi, Parisa
    Giamo, Taylor
    Arnold, Gwen
    Alliende, Mateo
    Huynh, Elisabeth
    Lea, Jaclyn
    Lucine, Rachel
    Tillett Miller, Alexandria
    Webre, Alana
    Yee, Aneka
    Champagne-Zamora, Adrianna
    Taylor, Keith
    REVIEW OF POLICY RESEARCH, 2022, 39 (02) : 143 - 169
  • [48] Characterizing polysubstance use: What do we know about use of cigarettes, vaping products, cannabis, and alcohol among Canadians?
    Czoli, Christine
    Luongo, Gabriella
    Mischki, Trevor
    HEALTH REPORTS, 2023, 34 (04) : 16 - 22
  • [49] Postoperative agitation or delirium in paediatric patients. What we know and how to avoid it
    Segura, M. Lopez
    Busto-Aguirreurreta, N.
    REVISTA ESPANOLA DE ANESTESIOLOGIA Y REANIMACION, 2023, 70 (08): : 467 - 472
  • [50] What do we know about micronutrients in critically ill patients? A narrative review
    de Man, Angelique M. E.
    Stoppe, C.
    Koekkoek, W. A. C.
    Briassoulis, G.
    Subasinghe, S. D. L. P.
    Cobilinschi, C.
    Deane, A. M.
    Manzanares, W.
    Grintescu, I.
    Mirea, L.
    Roshdy, A.
    Cotoia, A.
    Bear, D. E.
    Boraso, S.
    Fraipont, V.
    Christopher, K. B.
    Casaer, M.
    Gunst, J.
    Pantet, O.
    Elhadi, M.
    Bolondi, G.
    Forceville, X.
    Angstwurm, M. W. A.
    Gurjar, M.
    Biondi, R.
    van Zanten, A. R. H.
    Berger, M. M.
    JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 2025, 49 (01) : 33 - 58